Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.

Saved in:
Bibliographic Details
Title: Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.
Authors: Epstein S; Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. Electronic address: see2132@cumc.columbia.edu., Xia Z; University of Pittsburgh; Department of Neurology; Pittsburgh, PA, USA., Lee AJ; Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA., Dahl M; University of Pittsburgh; Department of Neurology; Pittsburgh, PA, USA., Edwards K; The Multiple Sclerosis Center of Northeastern New York; Latham, NY, USA., Levit E; Yale University School of Medicine; Department of Neurology; New Haven, CT, USA., Longbrake EE; Yale University School of Medicine; Department of Neurology; New Haven, CT, USA., Perrone C; University of Pennsylvania School of Medicine; Department of Neurology; Philadelphia, PA, USA., Kavak K; State University of New York at Buffalo; Department of Neurology; Buffalo, NY, USA., Weinstock-Guttman B; State University of New York at Buffalo; Department of Neurology; Buffalo, NY, USA., Diallo F; Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA., Ricci A; Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA., Riley CS; Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA., De Jager PL; Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA., Farber R; Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA., Wesley SF; Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA.
Corporate Authors: Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative
Source: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2022 Jan; Vol. 57, pp. 103433. Date of Electronic Publication: 2021 Dec 02.
Publication Type: Journal Article; Observational Study
Journal Info: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2211-0356
DOI:10.1016/j.msard.2021.103433